Insmed Reports on Phase 2b CEDAR Study Outcomes and Future Directions Insmed Incorporated has released insights from its Phase 2b study on brensocatib, facing disappointing results in efficacy for hidradenitis suppurativa.

Insmed Reports on Phase 2b CEDAR Study Outcomes and Future Directions #USA #Bridgewater #Insmed #brensocatib #Hidradenitis_Suppurativa

Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis - PharmaTimes MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups

#PharmaTimes #pharma #pharmaceuticals #Brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #MHRA #MedicinesandHealthcareproductsRegulatoryAgency #marketingauthorisation #chroniccondition #dipeptidylpeptidase1 #inflammatoryprocess #lungs #respiratory #JulianBeach
zurl.co/LPYPc

Pomerantz Law Firm Launches Investigation into Insmed Incorporated on Behalf of Investors Following Stock Drop Pomerantz LLP is probing claims on behalf of Insmed investors after the company's recent stock plunge due to trial failures of brensocatib.

Pomerantz Law Firm Launches Investigation into Insmed Incorporated on Behalf of Investors Following Stock Drop #United_States #New_York #Pomerantz_LLP #brensocatib #Insmed_Incorporated

Cabildo Abierto Una plataforma para discutir en serio, hecha en Argentina.

cabildoabierto.ar/perfil/logo-ped.bsky.social

The Ultimate SEO Boost: Free Backlinks from aéPiot
#ROBINHOOD #THE #ANIMAL #RESCUER
allgraph.ro/advanced-sea...
#BRENSOCATIB
aepiot.ro/advanced-sea...

bsky.app/search?q=aéPiot
bsky.app/starter-pack...b

Insmed Announces Significant Updates in Clinical Trials and New Acquisition Strategy Insmed Incorporated reveals key outcomes from its clinical trials for brensocatib, alongside an exciting new acquisition that promises to enhance its therapeutic offerings.

Insmed Announces Significant Updates in Clinical Trials and New Acquisition Strategy #USA #Bridgewater #Insmed #brensocatib #monoclonal_antibody

CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, and other CHMP decisions.

#bronchiectasis #respiratory #CHMP #Insmed #brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #NCFB #ASPENtrial #Sanofi #Wayrilz #rilzabrutinib #immunethrombocytopenia #ITP #SanofiWinthrop #Rezurock #belumosudil #chronicgraftversushostdisease #GvHD #transplant #KadmonPharma
zurl.co/r27x2

Insmed’s BRINSUPRI™ Moves Closer to EU Approval for NCFB Treatment Insmed's BRINSUPRI™ (brensocatib) could become the first approved treatment for non-cystic fibrosis bronchiectasis in the EU, pending final regulatory decisions.

Insmed’s BRINSUPRI™ Moves Closer to EU Approval for NCFB Treatment #None #Insmed #brensocatib #BRINSUPRI™

Insmed to Showcase Key Data at ERS Congress 2025 in Amsterdam Insmed will present critical findings at the European Respiratory Society Congress 2025, focusing on innovative treatments for pulmonary diseases.

Insmed to Showcase Key Data at ERS Congress 2025 in Amsterdam #United_States #Bridgewater #Insmed #brensocatib #ERS_Congress

Couldn’t sleep last night processing all the fantastic news for our #bronchiectasis & #NTM community. Thank you Dr Daley & the NJH team for a fabulous patient conference‼️ #BRINSUPRI #brensocatib #AirwayClearance #CareCenters

Insmed Announces Strong Second-Quarter 2025 Revenue Growth and Updates Clinical Trajectory Insmed's second-quarter 2025 results show a 19% growth in revenue driven by ARIKAYCE, with exciting clinical updates on brensocatib and other therapies.

Insmed Announces Strong Second-Quarter 2025 Revenue Growth and Updates Clinical Trajectory #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Insmed Announces $750 Million Public Stock Offering to Enhance Biopharmaceutical Development Insmed has priced a $750 million public offering of common stock to support its biopharmaceutical innovations and expansion. This funding aims to drive advanced research and commercialization efforts.

Insmed Announces $750 Million Public Stock Offering to Enhance Biopharmaceutical Development #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Brensocatib Demonstrates Consistent Efficacy in Diverse Patient Groups According to ASPEN Study Analysis New data from Insmed's ASPEN study confirm that brensocatib is effective and safe across different patient subgroups with non-cystic fibrosis bronchiectasis, setting a new treatment standard.

Brensocatib Demonstrates Consistent Efficacy in Diverse Patient Groups According to ASPEN Study Analysis #United_States #Bridgewater #Insmed #brensocatib #Bronchiectasis

Insmed's First-Quarter 2025 Recap: Growth and Anticipated Milestones Ahead Insmed Incorporated has reported its financial results for Q1 2025, showcasing significant revenue growth and outlining milestones for upcoming drug approvals and studies.

Insmed's First-Quarter 2025 Recap: Growth and Anticipated Milestones Ahead #United_States #Bridgewater #Insmed #ARIKAYCE #brensocatib

Brensocatib Offers Breakthrough for Untreated Lung Disease A groundbreaking global trial reveals brensocatib, a once-daily oral medication, as a promising new treatment for bronchiectasis—offering hope for improved lung function and quality of life in a disease with no FDA-approved therapies.

A new oral drug shows promise in treating bronchiectasis, reducing exacerbations and improving lung function. Hope is on the horizon. #Brensocatib #LungHealth #MedicalBreakthrough

To whom it may concern - hoffnungsvolle Nachricht des Tages
#Brensocatib #Mukoviszidose

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...

Phase 3 Trial of the DPP-1 Inhibitor #Brensocatib in #Bronchiectasis
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....

Promising Results of Insmed's Brensocatib for Bronchiectasis Published in NEJM The New England Journal of Medicine features results from Insmed's pivotal study on brensocatib, highlighting significant improvements for bronchiectasis patients. A groundbreaking step in treatment.

Promising Results of Insmed's Brensocatib for Bronchiectasis Published in NEJM #USA #Bridgewater #Insmed #brensocatib #Bronchiectasis

Insmed's Brensocatib Application Progresses with FDA Priority Review Insmed announces that the FDA will not convene a meeting regarding Brensocatib for bronchiectasis, with a target action date set for August 2025.

Insmed's Brensocatib Application Progresses with FDA Priority Review #United_States #FDA #Bridgewater #Insmed #brensocatib

Insmed's Impressive 2024 Financial Performance and Growth Outlook Insmed Incorporated reports strong revenues for 2024 and anticipates continued growth driven by ARIKAYCE® and upcoming product launches. Discover the company's strategic updates.

Insmed's Impressive 2024 Financial Performance and Growth Outlook #USA #Bridgewater,_New_Jersey #Insmed #ARIKAYCE #brensocatib

Insmed's Brensocatib Receives FDA Priority Review for Bronchiectasis Treatment, Target Action Date August 2025 Insmed's brensocatib has been granted Priority Review by the FDA, potentially becoming the first approved treatment for bronchiectasis. Decision expected by August 2025.

Insmed's Brensocatib Receives FDA Priority Review for Bronchiectasis Treatment, Target Action Date August 2025 #United_States #Bridgewater #Insmed #brensocatib #Bronchiectasis

Insmed's Business Update Highlights Promises for 2025 Growth at J.P. Morgan Conference Insmed Incorporated announced impressive revenue forecasts and upcoming product launches at the 43rd J.P. Morgan Healthcare Conference, highlighting a strong business outlook.

Insmed's Business Update Highlights Promises for 2025 Growth at J.P. Morgan Conference #USA #San_Francisco #Insmed #ARIKAYCE #brensocatib